Vitrakvi

Vitrakvi is a brand name for the drug tivozanib, which is a tyrosine kinase inhibitor. It is used in the treatment of relapsed or refractory advanced renal cell carcinoma (RCC) in adults who have received at least two prior systemic therapies. Renal cell carcinoma is a type of kidney cancer.

Tivozanib works by blocking the activity of specific proteins, called vascular endothelial growth factor receptors (VEGFRs). These receptors play a role in the growth of new blood vessels, which tumors need to grow and spread. By inhibiting VEGFRs, tivozanib aims to reduce the blood supply to the tumor, thereby slowing or stopping its growth.

The effectiveness and safety of tivozanib have been evaluated in clinical trials. These studies have shown that tivozanib can lead to improvements in progression-free survival and objective response rates in patients with advanced RCC who have not responded well to previous treatments.

Vitrakvi is administered orally, typically as a capsule. The dosage and duration of treatment are determined by a healthcare professional based on the individual patient's condition and response to the medication. As with any medication, Vitrakvi can cause side effects, which may include fatigue, diarrhea, hypertension, and nausea. Patients are advised to discuss any potential side effects with their doctor. The use of Vitrakvi is generally recommended for patients whose cancer has progressed after other treatments.